$XBIO
Xenetic Biosciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000168316823005513 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $611.2K $651.0K
YoY Change 47.54% 56.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $740.0K $946.0K
YoY Change -14.28% -7.83%
% of Gross Profit
Research & Development $1.021M $903.2K
YoY Change 155.92% -56.52%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.758M $1.849M
YoY Change 39.29% -40.42%
Operating Profit -$1.147M -$1.198M
YoY Change 35.26% -55.41%
Interest Expense $90.00K $126.1K
YoY Change 97.89% 689.61%
% of Operating Profit
Other Income/Expense, Net $91.13K $147.2K
YoY Change 108.21% 888.82%
Pretax Income -$1.060M -$1.051M
YoY Change 31.84% -60.67%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.056M -$1.051M
YoY Change 31.29% -60.67%
Net Earnings / Revenue -172.71% -161.44%
Basic Earnings Per Share -$0.69 -$0.69
Diluted Earnings Per Share -$0.69 -$0.69
COMMON SHARES
Basic Shares Outstanding 1.533M shares 15.17M shares
Diluted Shares Outstanding 1.533M shares 1.525M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.780M $10.73M
YoY Change -29.38% -28.15%
Cash & Equivalents $9.776M $10.73M
Short-Term Investments
Other Short-Term Assets $1.480M $1.319M
YoY Change 363.8% 193.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.26M $12.04M
YoY Change -20.54% -21.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $704.4K $704.4K
YoY Change -49.89% -35.49%
Total Long-Term Assets $704.4K $704.4K
YoY Change -49.89% -35.49%
TOTAL ASSETS
Total Short-Term Assets $11.26M $12.04M
Total Long-Term Assets $704.4K $704.4K
Total Assets $11.96M $12.75M
YoY Change -23.19% -22.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $448.6K $221.3K
YoY Change 121.21% -53.19%
Accrued Expenses $620.0K $650.0K
YoY Change -26.89% -19.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.068M $871.3K
YoY Change 1.68% -31.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.068M $871.3K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.068M $871.3K
YoY Change 1.68% -31.89%
SHAREHOLDERS EQUITY
Retained Earnings -$192.1M -$191.0M
YoY Change 2.37% 2.25%
Common Stock $1.536K $1.536K
YoY Change -89.29% -89.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.89M $11.88M
YoY Change
Total Liabilities & Shareholders Equity $11.96M $12.75M
YoY Change -23.19% -22.58%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.056M -$1.051M
YoY Change 31.29% -60.67%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$950.0K -$1.269M
YoY Change -11.98% 74.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -950.0K -1.269M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities
Net Change In Cash -950.0K -1.269M
YoY Change -11.98% 3.27%
FREE CASH FLOW
Cash From Operating Activities -$950.0K -$1.269M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$950.0K -$1.269M
YoY Change 64.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001534525
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37937
dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
778-7720
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1532600 shares
CY2023Q2 us-gaap Cash
Cash
10725707 usd
CY2022Q4 us-gaap Cash
Cash
13097265 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1319035 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
556094 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12044742 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13653359 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
704431 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1066931 usd
CY2023Q2 us-gaap Assets
Assets
12749173 usd
CY2022Q4 us-gaap Assets
Assets
14720290 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
221281 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287360 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
650034 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
785796 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
871315 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1073156 usd
CY2023Q2 us-gaap Liabilities
Liabilities
871315 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1073156 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1535301 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1519360 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1532600 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1516659 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1536 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1520 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207908129 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207769904 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191007135 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189099618 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12749173 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14720290 usd
CY2023Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
651005 usd
CY2022Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
416710 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1256849 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
805703 usd
CY2023Q2 us-gaap Revenues
Revenues
651005 usd
CY2022Q2 us-gaap Revenues
Revenues
416710 usd
us-gaap Revenues
Revenues
1256849 usd
us-gaap Revenues
Revenues
805703 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
903243 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2077499 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1498519 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3178898 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
945950 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1026290 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1871693 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1933599 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1849193 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3103789 usd
us-gaap Operating Expenses
OperatingExpenses
3370212 usd
us-gaap Operating Expenses
OperatingExpenses
5112497 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1198188 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2687079 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2113363 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4306794 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21122 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1076 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25642 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-877 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
126103 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
15965 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
180204 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
41870 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
147225 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14889 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
205846 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40993 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1050963 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2672190 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.10
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1524717 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1524717 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1406657 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1406657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1520710 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1520710 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1375505 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1375505 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12859432 usd
CY2023Q2 xbio Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 shares
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69389 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1050963 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
xbio Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138241 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16920241 usd
CY2022Q2 xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
135870 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2672190 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
255465 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
0 usd
xbio Research And Developments In Process
ResearchAndDevelopmentsInProcess
1305000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
19087 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
138241 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
255465 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
762941 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-11579 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-362500 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-201841 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-141920 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2371558 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2816590 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
-0 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2371558 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3316590 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10725707 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14927440 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
0 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
805000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 Reverse Stock Split
CY2023Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
138241 usd
us-gaap Share Based Compensation
ShareBasedCompensation
255465 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
37000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
69389 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
135870 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39000000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38600000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
19087 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9611 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9611 usd

Files In Submission

Name View Source Status
0001683168-23-005513-index-headers.html Edgar Link pending
0001683168-23-005513-index.html Edgar Link pending
0001683168-23-005513.txt Edgar Link pending
0001683168-23-005513-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20230630.xsd Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-063023.htm Edgar Link pending
xbio-20230630_cal.xml Edgar Link unprocessable
xbio-20230630_lab.xml Edgar Link unprocessable
xbio-20230630_pre.xml Edgar Link unprocessable
xenetic_i10q-063023_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
xbio-20230630_def.xml Edgar Link unprocessable